联环药业：拟5000万元增资全资子公司联环投资

Core Viewpoint - The company plans to increase its investment in its wholly-owned subsidiary, Yangzhou Lianhuan Investment Co., Ltd., by 50 million yuan to enhance its capital strength and operational capabilities, thereby improving its competitiveness in the global pharmaceutical market and promoting the development of innovative drugs and international market expansion [1] Group 1 - The company is increasing its investment in its subsidiary by 50 million yuan [1] - The purpose of the capital increase is to enhance the subsidiary's capital strength and operational capabilities [1] - The move aims to strengthen the company's competitiveness in the global pharmaceutical market [1] Group 2 - The investment will support the development of innovative drugs [1] - The company seeks to expand its presence in international markets [1]